Modernatx, Inc.

Moderna Therapeutics, Inc.

Antonin De Fougerolles

Justin Guild

Sayda Mahgoub Elbashir

Tirtha Chakraborty

Atanu Roy

Stephen G Hoge

Stephane Bancel

Noubar Boghos Afeyan

Susan Whoriskey

Matthias John

Matthew G Stanton

Gabor Butora

Jason P Schrum

Joshua P Frederick

Jeff Lynn Ellsworth

Kenechi Ejebe

Kristy M Wood

Paul Hatala

Örn Almarsson

Andrew W Fraley

John Podobinski

Yuxun Wang

Divakar Ramakrishnan

Christopher R Conlee

David D Hile

Pedro Valencia

Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.

Delivery and formulation of engineered nucleic acids

The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.

Terminally modified RNA

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of signal-sensor polynucleotides, primary transcripts and mmRNA molecules.

Signal-sensor polynucleotides for the alteration of cellular phenotypes

The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins

Terminally Modified RNA

The invention relates to a pharmaceutical composition including a plurality of lipid nanoparticles having a mean particle size of between 80 nm and 160 nm and containing an mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5'-cap, 5&#x2032;-UTR, a 3&#x2032;-UTR, and a poly-A region with at least 100 nucleotides.

Modified Polynucleotides for the production of biologics and proteins associated with human disease

A pharmaceutical composition which has a plurality of lipid nanoparticles that has a mean particle size of between 80 nm and 160 nm and contains a modified mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5'-cap, 5&#x2032;-UTR, N1-methyl-pseudouridine, a 3&#x2032;-UTR, and a poly-A region with at least 100 nucleotides.

Modified polynucleotides for the production of secreted proteins

In vivo production of proteins

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

Modified polynucleotides

Modified polynucleotides for the production of oncology-related proteins and peptides

Growing community of inventors

Waterloo, Belgium

Antonin De Fougerolles